Docstoc

CDC Introduction to the Chronic Disease Cost

Document Sample
CDC Introduction to the Chronic Disease Cost Powered By Docstoc
					Introduction to the Chronic Disease Cost Calculator
Presented by Diane Orenstein, Ph.D., and Justin Trogdon, Ph.D.
                        April 1, 2010
        Purpose of the CDCC (1 of 2)
   Estimate medical expenditures at the state level separately by
    insured population for the following select chronic diseases:
        Arthritis
        Asthma
        Cancer
        Cardiovascular disease (CVD), including
            Congestive heart failure (CHF)
            Coronary heart disease (CHD)
            Hypertension
            Stroke
            Other CVD (including other cerebrovascular disease)
        Depression
        Diabetes
   Estimates of medical expenditures are provided for the entire
    state population (all payers, including the uninsured) and
    separately for Medicaid, Medicare, and privately insured.
    Purpose of the CDCC (2 of 2)
   Estimate absenteeism costs for the
    above chronic diseases at the state
    level.

   Allow the user to generate estimates of
    the costs of selected chronic diseases
    using customized inputs.

   Project estimates of the medical costs of
    selected chronic diseases in the near
    future.
         Accessing the CDCC
   Download Version 1 of the software at
    http://www.cdc.gov/nccdphp/resources/calculator.htm
    What’s New in Version 2
   Estimates of the prevalence and costs of
    Asthma, Arthritis and Depression
   Expanded estimates of the medical costs
    from Medicaid only to Medicare, private
    insurance, and “all payers”
   Estimates of absenteeism costs
   Projections of future medical costs (10
    years)
   Charts
             Intended Audience
   Chronic disease directors
   State Medicaid directors
   Other state and federal policy and
    decision makers
   Federal agencies and others interested
    in reviewing the burden of chronic
    disease across states and across the
    nation
               Intended Use
   Provide estimates of medical expenditures and
    absenteeism costs due to select chronic
    diseases at the state level.
       Many states do not have the resources
        (financial and personnel) to do this
        themselves
   Help policymakers quantify and understand the
    financial impact caused by chronic diseases
   Inform decisions on investments in chronic
    disease prevention and disease management
    programs
DRAFT—Please do not
cite
What the Calculator
Does
   Estimates for arthritis, asthma, cancer,
    cardiovascular disease (CHF, CHD,
    hypertension, stroke, and other CVD),
    depression, and diabetes at the state
    level: 1) prevalence, 2) medical costs by
    payer, and 3) absenteeism costs
   Minimizes double-counting of Medicaid
    dollars going to multiple diseases
   Creates sound estimates with no
    additional data required
   Allows users to input their own data in
    place of default estimates
What the Calculator
Does Not Do
   Does not provide exact prevalence or
    medical and absenteeism costs of the
    chronic diseases for each state—only
    estimates
   Not designed for comparisons across
    states
   Does not include other costs of chronic
    disease, including productivity losses
    and reductions in the quality of life
   Does not make policy or value
    judgments on spending for chronic
    disease
             Next Steps
   Update source data (e.g., MEPS)
    through 2007, the most recent year
    available
   Expected release—Summer 2010
          Investigators
   CDC Investigators
        Diane Orenstein (DHDSP)
        Isaac Nwaise (DHDSP)
        Brett Miner (DHDSP)
        Nicole Blair (DHDSP)
        Florence Tangka (DCPC)
        Donatus Ekwueme (DCPC)
        Rui Li (DDT)
        Tursynbek Nurmagambetov (NCEH)
        Louise Murphy (DACH)
        Daniel Chapman (DACH)

   RTI Investigators
        Susan Haber
        Eric Finkelstein
        Justin Trogdon
        Other Collaborators
   Agency for Healthcare Research and Quality
    (AHRQ)
   National Association of Chronic Disease
    Directors (NACDD)
       Especially Chris Maylahn and John Robitscher
   National Pharmaceutical Council (NPC)
   External Review Panel
     Ken Thorpe (Emory)
     Steve Teutsch (Merck)

     Allison Rosen (U. of Michigan)